Alzheimer's Disease and Parkinson's Disease
Open accessThe DOI matches its Crossref record; 106 of the 107 references it cites were found in a registry or an index.
Abstract
Although most cases of Alzheimer's and Parkinson's disease are sporadic, some cases are clearly familial. This review, part of the Genomic Medicine series, examines the genetics of these familial forms. Although the inherited forms are rare, the knowledge derived from investigating their pathobiology has improved our understanding of the pathobiology of the more common, sporadic forms of the diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general terms, neurodegenerative diseases are thought to be driven by the accumulation of neurotoxic material such as amyloid beta (Aβ) or myelin debris in the central nervous system (CNS) (Nussbaum and Ellis, 2003; Trapp and Nave, 2008).”
From SYK coordinates neuroprotective microglial responses in neurodegenerative disease (2022) · cites this paper as Nussbaum and Ellis, 2003
In the citing paper
“PD pathology is mainly characterized by loss of neurons from the substantia nigra pars compacta in association with the accumulation of ubiquitinated alpha synuclein and other proteins in cytoplasmic inclusions (Lewy bodies) and thread-like proteinaceous inclusions within neurites (Lewy neuritis).”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [4]
In the citing paper
“However, Lewy bodies are also seen in the cerebral cortex, brainstem nuclei, limbic system, sympathetic ganglia, nucleus basalis of Meinert and myenteric plexus [4].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [4]
In the citing paper
“This review is focused on the potential of herbal medicine in AD since it is responsible for more than two-thirds of all dementia cases [5,6].”
From Indian Medicinal Herbs and Formulations for Alzheimer’s Disease, from Traditional Knowledge to Scientific Assessment (2020) · cites this paper as [6]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378 · cited 4×
“Increased Abeta42(43) from cell lines expressing presenilin 1 mutations.”
BackgroundInfluentialSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Self-citationMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Research works printed but not linked: 5
- 10.1001/archinte.151.5.989 · doi:10.1001/archinte.151.5.989 · Paper page
- Clark CM, Ewbank D, Lee VM-Y, Trojanowski JQ. Molecular pathology of Alzheimer's disease: neuronal cytoskeletal abnormalities. In: Growdon JH, Rossor MN, eds. The dementias. Vol. 19 of Blue books of practical neurology. Boston: Butterworth–Heinemann, 1998:285-304.
- Duvoisin RC, 1996, Adv Neurol, 69, 33
- Louis ED, 1996, Adv Neurol, 69, 311
- Matsumine H, 1997, Am J Hum Genet, 60, 588
Cited by
Items 601–700 of 1,000
Guzman-Sanchez, F., Valdivieso, F., & Burgos, J. S. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120070 · Cited by 22
“accepted as being associated with non-familial AD: aging [2–4] and possession of the apolipoprotein E ε4”
Genetic Epidemiology of Alzheimer Disease
Mayeux, R. P. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200607001-00008 · Cited by 30
Kodali, M., Kadiri, S. R., & Alku, P. (2024) · Computer Speech & Language · doi:10.1016/j.csl.2023.101548 · Cited by 24
How close are we to individualized medicine for Parkinson’s disease?
Kim, H. J., & Jeon, B. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1182021 · Cited by 25
Quantum dot: Heralding a brighter future in neurodegenerative disorders
Singh, A., Mallika, T. N., Gorain, B., Yadav, A. K., Tiwari, S., Flora, S. J. S., Shukla, R., & Kesharwani, P. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102700 · Cited by 27
Kashyap, K., & Siddiqi, M. I. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10274-8 · Cited by 24
Jackson, H., Anzures‐Cabrera, J., Taylor, K. I., Pagano, G., PASADENA Investigators, & Prasinezumab Study Group (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.765765 · Cited by 25
Abraham, A., Bay, A. A., Ni, L., Schindler, N., Singh, E., Leeth, E., Bozzorg, A., Hart, A. R., & Hackney, M. E. (2023) · PLoS ONE · doi:10.1371/journal.pone.0272952 · Cited by 28
“PD affects about 1% of individuals over 60 years of age [4], and more than 10 million men and women worldwide, including 1,238,000 Americans by the year 2030 [5].”
BackgroundRevisiting Alpha-Synuclein Pathways to Inflammation
Lyra, P., Machado, V., Rota, S., Chaudhuri, К. R., Botelho, J., & Mendes, J. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087137 · Cited by 26
Gait video-based prediction of unified Parkinson’s disease rating scale score: a retrospective study
Eguchi, K., Takigawa, I., Shirai, S., Takahashi‐Iwata, I., Matsushima, M., Kano, T., Yaguchi, H., & Yabe, I. (2023) · BMC Neurology · doi:10.1186/s12883-023-03385-2 · Cited by 26
Talbot, N. C., Luther, P. M., Spillers, N. J., Ragland, A. R., Kidder, E. J., Kelkar, R. A., Varrassi, G., Ahmadzadeh, S., Shekoohi, S., & Kaye, A. D. (2023) · Cureus · doi:10.7759/cureus.50948 · Cited by 25
Epigenetic Research of Neurodegenerative Disorders Using Patient iPSC‐Based Models
Fernández‐Santiago, R., & Ezquerra, M. (2015) · Stem Cells International · doi:10.1155/2016/9464591 · Cited by 24
Rajapakse, H. A., Nantermet, P. G., Selnick, H. G., Barrow, J. C., McGaughey, G. B., Munshi, S. K., Lindsley, S. R., Young, M. B., Ngo, P. L., Holloway, M. K., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.137 · Cited by 24
Distributed Intelligent Sensor Network for the Rehabilitation of Parkinson's Patients
Hong, Y., Schlösser, M., Schnitzer, A., Schäfer, T., Schläfke, M. E., Leonhardt, S. K., & Schiek, M. (2010) · IEEE Transactions on Information Technology in Biomedicine · doi:10.1109/titb.2010.2095463 · Cited by 24
Xiao, R., Miller, J. A., Lubelski, D., Alberts, J. L., Mroz, T. E., Benzel, E. C., Krishnaney, A. A., & Machado, A. G. (2016) · The Spine Journal · doi:10.1016/j.spinee.2016.07.530 · Cited by 24
“3% of the US population and 1% of individuals over 60 years of age [1,2].”
BackgroundShen, W., Wang, L., Pi, R., Li, Z., & Wang, R. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.07.035 · Cited by 25
Cosden, M., Jinn, S., Yao, L., Gretzula, C. A., Kandebo, M., Toolan, D., Hatcher, N. G., Ma, L., Lemaire, W., Adam, G. C., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105507 · Cited by 23
Microglia Process α‐Synuclein Fibrils and Enhance their Pathogenicity in a TREM2‐Dependent Manner
Xiong, M., Xia, D., Yu, H., Meng, L., Zhang, X., Chen, J., Tian, Y., Yuan, X., Niu, X., Nie, S., et al. (2024) · Advanced Science · doi:10.1002/advs.202413451 · Cited by 28
Perhoč, A. B., Barilar, J. O., Knezović, A., Farkaš, V., Bagarić, R., Švarc, A., Grünblatt, E., Riederer, P., & Šalković‐Petrišić, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.12.018 · Cited by 24
“Alzheimer's disease (AD) is the most common neurodegenerative disease associated with irreversible loss of neurons and progressive cognitive impairment (Nussbaum and Ellis, 2003).”
Novel therapeutic strategies targeting mitochondria as a gateway in neurodegeneration
Trigo, D., Vitória, J., & Silva, O. A. B. D. C. E. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.355750 · Cited by 23
Wang, S., Yang, L., He, W., Zheng, M., & Zou, Y. (2024) · Small Methods · doi:10.1002/smtd.202400096 · Cited by 29
Park, H., & Oh, M. (2012) · Human & Experimental Toxicology · doi:10.1177/0960327111433898 · Cited by 23
Lee, J. Y., Han, J. H., Kim, H., Jeon, B. S., Kim, D. G., & Paek, S. H. (2008) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2008.44.1.26 · Cited by 23
Postoperative cognitive dysfunction and Alzheimer disease
Işık, B. (2015) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1405-87 · Cited by 27
“Inhaled anesthetic modulation of amyloid beta(1-40) assembly and growth.”
BackgroundPredictors of clinically meaningful change in PDQ-39 in Parkinson's disease
Margolius, A. J., Cubillos, F., He, Y., Wu, S. S., Schmidt, P. N., & Simuni, T. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.06.034 · Cited by 23
Vivar-Estudillo, G., Almanza-Ojeda, D.-L., Cheng, I., Gómez, J. C., Andrade-Lucio, J. A., & Ibarra-Manzano, M.-A. (2019) · Sensors · doi:10.3390/s19092072 · Cited by 26
“This disease is considered the second most common disorder after Alzheimer’s disease [1] and is associated with progressive neuronal loss of the substantia nigra and other brain structures [2].”
BackgroundAntonazzo, M., Botta, M. F., Bengoetxea, H., Ruíz-Ortega, J. Á., & Morera‐Herreras, T. (2019) · International review of neurobiology · doi:10.1016/bs.irn.2019.06.012 · Cited by 25
RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson’s Disease
Ahlers‐Dannen, K. E., Spicer, M. M., & Fisher, R. A. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.118836 · Cited by 24
“…considered an idiopathic disorder (Fearnley and Lees, 1991) with identifiable genetic mutations a t A SP ET J ou r n a l s on A p r il 13 , 2024 m o l ph a r m . a s p e tj ou r n a l s . o r g D o w n l o a d e d fr o m accounting for only 5% – 9% of clinical cases (Nussbaum and Ellis, 2003).”
BackgroundComputational approaches for understanding the diagnosis and treatment of Parkinson's disease
Smith, S. L., Lones, M. A., Bedder, M., Alty, J., Cosgrove, J., Maguire, R. J., Pownall, M. E., Ivanoiu, D., Lyle, C., Cording, A., et al. (2015) · IET Systems Biology · doi:10.1049/iet-syb.2015.0030 · Cited by 26
Buyukturkoglu, K., Rana, M., Ruíz, S., Hackley, S. A., Soekadar, S. R., Birbaumer, N., & Sitaram, R. (2013) · International IEEE/EMBS Conference on Neural Engineering · doi:10.1109/ner.2013.6696025 · Cited by 27
Lee, R. H., Tseng, T.-Y., Wu, C. Y., Chen, P., Chen, M., Kuo, J., & Lee, T. J.-F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040326 · Cited by 25
Possible Anti-Parkinson’s Disease Therapeutics From Nature: A Review
Dey, A., & De, J. N. (2015) · Studies in natural products chemistry · doi:10.1016/b978-0-444-63460-3.00009-2 · Cited by 23
Robinson, D. M., & Plosker, G. L. (2006) · CNS Drugs · doi:10.2165/00023210-200620080-00006 · Cited by 25
Pereira, C. P. M., Francis-Oliveira, J., Singulani, M. P., Ferreira, A. F. F., & Britto, L. R. G. (2023) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2023.578019 · Cited by 22
Alarcón‐Espósito, J., Mallea, M., & Rodríguez-Lavado, J. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200914155951 · Cited by 26
Peña‐Díaz, S., Pujols, J., Pinheiro, F., Santos, J., Pallarès, I., Navarro, S., Conde-Giménez, M., García, J., Salvatella, X., Dalfó, E., et al. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.588947 · Cited by 24
Pérez‐López, C., Hernández‐Vara, J., Caballol, N. S., Bayés, À., Buongiorno, M., López-Ariztegui, N., Gironell, A., López‐Sánchez, J. D., Martínez‐Castrillo, J. C., Álvarez, S. M., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.835249 · Cited by 22
“5%, which increases to 1% among people aged 65 to 69 years and 1–3% in people aged over 80 (3, 4).”
BackgroundHosomoto, K., Sasaki, T., Yasuhara, T., Kameda, M., Sasada, S., Kin, I., Kuwahara, K., Kawauchi, S., Okazaki, Y., Yabuno, S., et al. (2023) · Brain stimulation · doi:10.1016/j.brs.2023.03.003 · Cited by 23
“Parkinson's disease (PD) is a common neurodegenerative disease, characterized by the loss of dopamine (DA) neurons in the substantia nigra pars compacta (SNpc) [1,2].”
Hashim, F. A., Neggaz, N., Mostafa, R. R., Abualigah, L., Damaševičius, R., & Hussien, A. G. (2023) · Neural Computing and Applications · doi:10.1007/s00521-023-08936-9 · Cited by 22
Fama, R., Rosenbloom, M. J., Sassoon, S. A., Rohlfing, T., Pfefferbaum, A., & Sullivan, E. V. (2014) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9286-4 · Cited by 23
Psychopharmacological Neuroprotection in Neurodegenerative Disease: Heuristic Clinical Applications
Lauterbach, E. C., Shillcutt, S. D., Victoroff, J., Coburn, K. L., & Mendez, M. F. (2010) · Journal of Neuropsychiatry · doi:10.1176/jnp.2010.22.2.130 · Cited by 25
Impact of Sjogren's syndrome on Parkinson’s disease: A nationwide case-control study
Wu, M.-C., Xu, X., Chen, S.-M., Tyan, Y.-S., Chiou, J., Wang, Y., Lin, L.-C., Chen, C., & Wei, J. C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175836 · Cited by 22
Levodopa in Parkinson’s Disease: A Review of Population Pharmacokinetics/Pharmacodynamics Analysis
Marsot, A., Guilhaumou, R., Azulay, J., & Blin, O. (2017) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j30h04 · Cited by 22
Lee, Y., Kim, M., & Lee, J. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0960-8 · Cited by 23
Luo, Z., Lv, H., Chen, Y., Xu, X., Liu, K., Li, X., Deng, Y., & Zhou, Y. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.625042 · Cited by 26
“affects about 1% of individuals aged above 60 years and 5% of individuals over 85 years (16).”
BackgroundMelatonin attenuates MPP+-induced apoptosis via heat shock protein in a Parkinson's disease model
Jung, Y. J., Choi, H., & Oh, E. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.06.099 · Cited by 23
Yu, B., Zhou, C., Zhang, J., Ling, Y., Hu, Q., Wang, Y., & Bai, K. (2014) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2014/743541 · Cited by 26
Tomoregulin‐2 is found extensively in plaques in Alzheimer's disease brain
Siegel, D. A., Davies, P. J., Dobrenis, K., & Huang, M. K. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03801.x · Cited by 24
“Importantly, estimates of inherited forms of AD, which range from as little as 5% to more than 50% (Campion et al. 1999; Nussbaum and Ellis 2003; Selkoe 2001), suggest that other genes, acting through distinct pathways or at distinct entry points in a common pathway, probably contribute to AD.”
BackgroundBhandari, R., Gyawali, S., Aryal, N., Gaire, D., Paudyal, K., Panta, A., Panth, P., Joshi, D. R., Rokaya, R. K., Aryal, P., et al. (2021) · The Scientific World JOURNAL · doi:10.1155/2021/6649574 · Cited by 24
“Immunological studies have shown that neuronal cell damage caused by inflammation can induce AD and prolonged use of anti-inflammatory agents can reduce the severity of this disease by inhibiting onset and the progression of AD [1, 23].”
BackgroundUnveiling Interpretability in Self-Supervised Speech Representations for Parkinson's Diagnosis
Gimeno-Gómez, D., Botelho, C., Pompili, A., Abad, A., & Martínez-Hinarejos, C.-D. (2025) · IEEE Journal of Selected Topics in Signal Processing · doi:10.1109/jstsp.2025.3539845 · Cited by 37
Dental pulp stem cells and the management of neurological diseases: An update
Mortada, I., Mortada, R., & Bazzal, M. A. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24122 · Cited by 21
Camargo, L. C., Campos, G. A. A., Galante, P., Biolchi, A. M., Gonçalves, J. C., Lopes, K. S., & Mortari, M. R. (2017) · Neuropeptides · doi:10.1016/j.npep.2017.11.010 · Cited by 21
Baranowski, B. J., Hayward, G. C., Fajardo, V. A., & MacPherson, R. E. K. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171150 · Cited by 26
“Progression of this disease typically results in irreparable damage to neurons primarily in the cortex and hippocampal regions, and is associated with a loss of cognitive functions, such as memory, thinking and reasoning, and language [3, 4].”
Rate of brain aging and APOE ε4 are synergistic risk factors for Alzheimer’s disease
Glorioso, C. A., Pfenning, A. R., Lee, S. S., Bennett, D. A., Sibille, E. L., Kellis, M., & Guarente, L. (2019) · Life Science Alliance · doi:10.26508/lsa.201900303 · Cited by 21
“(Nussbaum & Ellis, 2003).”
BackgroundLoading Amlodipine on Diamond Nanoparticles: A Novel Drug Delivery System
Alawdi, S. H., Eidi, H., Safar, M. M., & Abdel-Wahhab, M. A. (2020) · Nanotechnology Science and Applications · doi:10.2147/nsa.s232517 · Cited by 21
Chai, X., Diwakarla, S., Pustovit, R. V., McQuade, R. M., Natale, M. R. D., Ermine, C. M., Parish, C. L., Finkelstein, D. I., & Furness, J. B. (2020) · Neurogastroenterology & Motility · doi:10.1111/nmo.13893 · Cited by 22
Proffitt, C., Bidkhori, G., Moyes, D. L., & Shoaie, S. (2020) · Microorganisms · doi:10.3390/microorganisms8091381 · Cited by 24
“Alzheimer’s, the most common neurodegenerative disease, results in an unrepairable loss of neurons [50] whilst Parkinson’s disease, another common neurodegenerative disease, is commonly characterised by tremors, rigidity and instability [50].”
BackgroundMitochondrial Phenotypes in Parkinson’s Diseases—A Focus on Human iPSC-Derived Dopaminergic Neurons
Heger, L. M., Wise, R. M., Hees, J. T., Harbauer, A. B., & Burbulla, L. F. (2021) · Cells · doi:10.3390/cells10123436 · Cited by 21
Hu, Y., Wen, C., Cao, G., Wang, J., & Feng, Y. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136673 · Cited by 24
Intrinsic Disorder in Proteins Associated with Neurodegenerative Diseases
Uversky, V. N. (2008) · Focus on structural biology · doi:10.1007/978-1-4020-9434-7_2 · Cited by 30
Lee, J. H., Byeon, S. R., Kim, Y. S., Lim, S. J., Oh, S. J., Moon, D. H., Yoo, K. H., Chung, B. Y., & Kim, D. J. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.05.019 · Cited by 24
Valenzuela, R. W., Julio Sanhueza, C., & Valenzuela, A. (2012) · Journal of Nutritional Therapeutics · doi:10.6000/1929-5634.2012.01.01.6 · Cited by 23
Evolution of Tertiary Carbinamine BACE‐1 Inhibitors: Aβ Reduction in Rhesus CSF upon Oral Dosing
Nantermet, P. G., Rajapakse, H. A., Stanton, M., Stauffer, S. R., Barrow, J. C., Gregro, A. R., Moore, K. P., Steinbeiser, M. A., Swestock, J., Selnick, H. G., et al. (2008) · ChemMedChem · doi:10.1002/cmdc.200800308 · Cited by 24
Thilakawardhana, S. B., Everett, D. M., Murdock, P. R., Dingwall, C., & Owen, J. S. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.08.004 · Cited by 22
Stoppini, M., Andreola, A., Foresti, G., & Bellotti, V. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.12.025 · Cited by 21
Early diagnosis and therapy of Parkinson’s disease: can disease progression be curbed?
Kansara, S. G., Trivedi, A., Chen, S., Jankovic, J. J., & Le, W. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0840-9 · Cited by 22
“In industrialized countries, PD occurs in about 1 % in those over 60 years in age (Nussbaum and Ellis 2003).”
BackgroundSeijo‐Martínez, M., del Río, M. C., Alvarez, J. R., Prado, R. S., Salgado, E. T., Esquete, J. P., & Sobrido, M. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.02.015 · Cited by 21
Familial Frontotemporal Dementia: From Gene Discovery to Clinical Molecular Diagnostics
Van Deerlin, V. M., Gill, L. H., Farmer, J. M., Trojanowski, J. Q., & Lee, V. M.-Y. (2003) · Clinical Chemistry · doi:10.1373/49.10.1717 · Cited by 21
Neurodegenerative Diseases and Ageing
Walker, L., McAleese, K. E., Erskine, D., & Attems, J. (2019) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-981-13-3681-2_4 · Cited by 24
Commercial symptom monitoring devices in Parkinson’s disease: benefits, limitations, and trends
Rodríguez-Martín, D., & Pérez‐López, C. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1470928 · Cited by 22
Hou, Y., Yang, J., Luo, C., Ou, R., Zou, Y., Song, W., Gong, Q., & Shang, H. (2018) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2018.10.003 · Cited by 21
Agostini, S., Mancuso, R., Costa, A. S., Citterio, L. A., Guerini, F. R., Meloni, M., Navarro, J., & Clerici, M. (2021) · Vaccines · doi:10.3390/vaccines9070686 · Cited by 20
Cabreza, J. N., Solano, G. A., Ojeda, S. A. A., & Munar, V. (2022) · International Conference on Artificial Intelligence in Information and Communication (ICAIIC) · doi:10.1109/icaiic54071.2022.9722678 · Cited by 20
Rangasamy, S. B., Jana, M., Dasarathi, S., Kundu, M., & Pahan, K. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.01.009 · Cited by 21
Chernyuk, D., Callens, M., Polozova, M., Gordeev, A., Chigriai, M., Rakovskaya, A., Ilina, A., Pchitskaya, E. I., den Haute, C. V., Vervliet, T., et al. (2023) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2023.02.005 · Cited by 20
Paidi, R. K., Raha, S., Roy, A., & Pahan, K. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112717 · Cited by 20
Parkinson´s disease cardiovascular symptoms: A new complex functional and structural insight
Kincl, V., Panovský, R., Bočková, M., Rektor, I., Mojica‐Pisciotti, M. L., & Máchal, J. (2023) · European Journal of Neurology · doi:10.1111/ene.16110 · Cited by 20
“The 1-year incidence of PD varies from 8 to 18 cases per 100,000 subjects [1, 2].”
BackgroundThe plasma derived exosomal miRNA-483-5p/502-5p serve as potential MCI biomarkers in aging
Liu, T., Li, N., Pu, J., Zhang, C., Xu, K., Wang, W., Liu, L., Gao, L., Xu, X., & Tan, J. (2024) · Experimental Gerontology · doi:10.1016/j.exger.2023.112355 · Cited by 20
“The study demonstrated that the transient MCI can return to its normal state through proper intervention (Nussbaum and Ellis, 2003).”
BackgroundAssociation between sex, systemic iron variation and probability of Parkinson's disease
Mariani, S., Ventriglia, M. C., Simonelli, I., Bucossi, S., Siotto, M., Donno, S., Vernieri, F., & Squitti, R. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2015.1020113 · Cited by 22
Ko, N.-H., Laine, C. M., Fisher, B. E., & Valero‐Cuevas, F. J. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00151 · Cited by 21
“Parkinson’s disease (PD) is the second most common neurodegenerative disease in the United States, affecting about 1–2% of the population over age of 65 (Guttmacher et al., 2003; de Lau and Breteler, 2006; Weintraub et al., 2008).”
BackgroundRapid P1 SAR of brain penetrant tertiary carbinamine derived BACE inhibitors
Zhu, H., Young, M. B., Nantermet, P. G., Graham, S. L., Colussi, D. J., Lai, M., Pietrak, B., Price, E. A., Sankaranarayanan, S., Shi, X., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.005 · Cited by 20
Risk of fracture amongst patients with Parkinson’s disease and other forms of parkinsonism
Sleeman, I. J., Che, Z. C., & Counsell, C. E. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.05.026 · Cited by 20
Wojtowicz, A. L., Mohaddes, M., Odin, D., Bülow, E., Nemes, S., & Cnudde, P. H. J. (2019) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000000679 · Cited by 20
Bisht, I., Ambasta, R. K., & Kumar, P. (2020) · Neuropeptides · doi:10.1016/j.npep.2020.102078 · Cited by 20
The impact of obesity on brain iron levels and α-synuclein expression is regionally dependent
Han, J., Plummer, J., Liu, L., Byrd, A. L., Aschner, M., & Erikson, K. M. (2017) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1387720 · Cited by 21
How should we treat a patient with early Parkinson’s disease?
Tsouli, S. G., & Konitsiotis, S. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02371.x · Cited by 20
van der Cammen, T. J. M., Croes, E. A., Dermaut, B., de Jager, M., Cruts, M., Broeckhoven, C. V., & van Duijn, C. M. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52573.x · Cited by 26
Harris, C., Kiger, A. M., & Counsell, C. E. (2012) · Journal of Advanced Nursing · doi:10.1111/j.1365-2648.2012.06099.x · Cited by 20
Pharmacological Management of Psychosis in Elderly Patients with Parkinsonism
Hasnain, M., Vieweg, W. V. R., Baron, M. S., Beatty-Brooks, M., Fernandez, A., & Pandurangi, A. K. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.01.025 · Cited by 22
OCTA in neurodegenerative optic neuropathies: emerging biomarkers at the eye–brain interface
Asanad, S., Mohammed, I. S. K., Sadun, A. A., & Saeedi, O. J. (2020) · Therapeutic Advances in Ophthalmology · doi:10.1177/2515841420950508 · Cited by 21
Mehan, S., Kaur, G., Dudi, R., Rajput, M., & Kalra, S. (2017) · Open Journal of Parkinson s Disease and Treatment · doi:10.17352/ojpdt.000001 · Cited by 19
Fan, X., Wang, D., Hellman, B., Janssen, M. F., Bakker, G., Coghlan, R., Hursey, A., Matthews, H. F., & Whetstone, I. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15112538 · Cited by 19
“Parkinson’s disease (PD) is a degenerative movement disorder affecting 1–2% of the population aged over 60 years and is the second most common neurodegenerative disorder after Alzheimer’s disease [1,2].”
BackgroundSQSTM1/ p62 oligomerization contributes to Aβ-induced inhibition of Nrf2 signaling
Guo, C., Zhang, Y. L., Nie, Q., Cao, D., Wang, X., Wan, X., Liu, M., Cui, J., Sun, J., Bai, Y., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.05.018 · Cited by 19
Zhao, J., Li, Y., Li, Y., Xu, S., Tao, T., Ye, H., Zhang, J., & Fan, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.637319 · Cited by 19
“Keywords: α-synuclein, apoptosis, Parkinson’s disease, PNU-282987, nicotinic acetylcholine receptor INTRODUCTION Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s Disease (Nussbaum and Ellis, 2003).”
BackgroundCochran, E. J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0949-0.00006-6 · Cited by 19
Huo, L., Liang, X., Li, B., Liang, J., He, Y., Jia, Y., Jia, J., Gong, X., Yu, F., & Wang, X. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/908439 · Cited by 19
Pochmann, D., Peccin, P., da Silva, I. R. V., Dorneles, G., Peres, A., Nique, S., Striebel, V., & Elsner, V. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.03.021 · Cited by 17
CRISPR/Cas: An intriguing genomic editing tool with prospects in treating neurodegenerative diseases
Rahman, S., Datta, M., Kim, J., & Jan, A. T. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.014 · Cited by 21
Neurogenetics: insights into degenerative diseases and approaches to schizophrenia
Ross, C. A., & Margolis, R. L. (2005) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2005.07.001 · Cited by 25
Ushakiran, P., Haria, J., Rani, R., & Singh, S. K. (2025) · Tissue Barriers · doi:10.1080/21688370.2025.2537991 · Cited by 24
Metadata
- Authors
- Nussbaum, R. L., & Ellis, C. E.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Nussbaum, Robert L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1356-1364
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149522871
- Cited by
- 1,351
- References
- 107
- Citations by year
- 2026: 25 · 2025: 55 · 2024: 75 · 2023: 74 · 2022: 80 · 2021: 82 · 2020: 80 · 2019: 83 · 2018: 74 · 2017: 74 · 2016: 63 · 2015: 54 · 2014: 65 · 2013: 46 · 2012: 66
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, Parkinson's disease, genetic susceptibility, inherited neurodegenerative disorders
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Apolipoproteins E, Humans, Molecular Sequence Data, Nerve Tissue Proteins, Substantia Nigra, Prevalence, Amyloid beta-Protein Precursor, Lewy Bodies, Mutation, Missense, Parkinsonian Disorders, Synucleins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.